Bayesian performance, test operating characteristics, and the cost of missed cases
Tests in Use
● RDT (HRP2/pLDH)
● Microscopy (thick film)
● PCR (nested/qPCR)
Pop. = 10,000 persons
1,000 simulated screens
⚕ The same test sensitivity and specificity produce very different predictive values depending on background prevalence. Adjust prevalence, test characteristics, and screening strategy to observe how the surveillance pyramid changes — and how missed sub-patent infections sustain transmission.
Diagnostic Test
Test Characteristics
Sensitivity (Se)
P(T+ | Disease+)92%
Specificity (Sp)
P(T− | Disease−)97%
Sub-patent detection
Sensitivity for low-density infections10%
Epidemiological Setting
True prevalence
Including sub-patent infections10%
Sub-patent fraction
Of all true infections30%
Screening Strategy
Population coverage
Fraction screened/treated80%
Cost per treatment (ACT)
USD$2.5
Operating Metrics
PPV
—
pos. pred. value
NPV
—
neg. pred. value
Missed cases
—
per 10,000
False treats
—
per 10,000
NNS
—
need to screen
Total cost
—
per 10,000 pop.
Programme Cost Breakdown
Testing—
True-positive treatment—
False-positive treatment—
Total—
Confusion Matrix
Fig. I · N = 10,000
Test Positive
Test Negative
Disease +
Disease −
True Positive
—
Detected & treated
False Negative
—
Missed — reservoir
False Positive
—
Unnecessary Rx
True Negative
—
Correctly cleared
Adjust prevalence and test characteristics to observe how the cell counts shift.
PPV & NPV across Prevalence
Fig. II · Bayesian sweep
The vertical line marks the current prevalence. PPV collapses at low prevalence even with high sensitivity — the core Bayesian insight.
Test Comparison — ROC
Fig. III
Each test's operating point on the ROC plane. PCR dominates; microscopy and RDT trade sensitivity for cost.
Missed Cases vs Prevalence
Fig. IV
Missed infections per 10,000 screened. Sub-patent reservoir is invisible to RDT and microscopy.
Surveillance Pyramid & Transmission Reservoir
Fig. V
Stacked bar showing the fate of all true infections under the current screening strategy. Missed sub-patent infections sustain onward transmission.